Author:
Jung Song-yi,Malhotra Poonam,Nguyen Kiana C.,Salzman David,Qi Yue,Pak Ethan H.,King Joshua,Vlashi Erina,Ann David,Weidhaas Joanne B.
Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology
Reference34 articles.
1. Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A, et al. The 21 nucleotide let-7 RNA regulates C. elegans developmental timing. Nature. 2000;403:901–6.
2. Cipollini M, Landi S, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in cancer management and research. Pharmgenomics Pers Med. 2014;7:173–91.
3. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3’ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68:8535–40.
4. Paranjape T, Heneghan H, Lindner R, Keane F, Hoffman A, Hollestelle A, et al. A 3’-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol. 2011;12:377–86.
5. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010;70:6509–15.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献